-- Company's third bi-specific DART® molecule, MGD010, in clinical testing -- FDA clears IND for fourth DART, MGD011 - Janssen to initiate clinical testing -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 ROCKVILLE, Md.

ROCKVILLE, Md. , April 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Wednesday, May 6, 2015 , the Company will release its financial results for the quarter ended March 31, 2015 . The Company's management team will host a conference call discussing the

ROCKVILLE, Md. , April 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md. , April 20, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md. , April 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Rockville, MD , April 7, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

-- First autoimmune DART(r) to enter the clinic -- MacroGenics to receive $3 million milestone payment from Takeda

-- Four oncology molecules in clinical development, including two bi-specific DART® molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash runway extends into 2018 ROCKVILLE, Md. , March 3, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc.

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig , M.D., Ph.D.,

MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, March 3, 2015 , the Company will release its financial results for the fourth quarter and full year 2014. The Company's management team will host a conference call discussing the Company's financial results and recent corporate

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig , M.D., Ph.D.,

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of the global collaboration and license agreement for

MacroGenics , Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, today announced that Scott Koenig ,

MacroGenics licenses MGD011 (CD19 x CD3 DART®) to Janssen $50 million upfront license fee paid to MacroGenics , and a $75 million equity investment by Johnson & Johnson Innovation - JJDC, Inc. MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S.

Results Support Initiation of Clinical Development of MGD011 in Hematological Malignancies

ROCKVILLE, Md. , Dec. 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

-- Four oncology molecules in clinical development; on track to have six by 2015 year-end -- Margetuximab Phase 3 study in metastatic breast cancer to initiate in 2015 -- MGD007 (gpA33 x CD3 DART) first patients dosed in colorectal cancer -- MGD011 (CD19 x CD3 DART) introduced ROCKVILLE, Md. , Nov.

New DART<font size="-1">^&reg;</font> Candidate: MGD011 Pre-clinical Data will be Highlighted

  MacroGenics to Present Pre-Clinical Data on MGD006 at 26 th EORTC-NCI-AACR Symposium ROCKVILLE, Md. , October 30, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the

ROCKVILLE, Md. , October 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, November 11, 2014 , the Company will release its financial results for the quarter ended September 30, 2014 . The Company's management team will host a conference call discussing

ROCKVILLE, Maryland and OSAKA, Japan , Sept. 29, 2014 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates.

ROCKVILLE, Md. , Aug. 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott

First DART(R) Molecule in Human Clinical Trial and Second DART Molecule Expected to Enter Clinic by End of Year

ROCKVILLE, Md. , July 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014 , the Company will release its financial results for the quarter ended June 30, 2014 . The Company's management team will host a conference call discussing the